C4X Discovery Holdings PLC C4XD forms Drug Discovery Advisory Network (8012K)
September 02 2019 - 2:00AM
UK Regulatory
TIDMC4XD
RNS Number : 8012K
C4X Discovery Holdings PLC
02 September 2019
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
C4X Discovery forms Drug Discovery Advisory Network
World-renowned drug discovery experts to advance C4XD
capabilities
2 September 2019 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, today announces that Robin Carr,
a renowned industry veteran who has worked at GSK and Astex, is to
head up and form a C4XD Drug Discovery Advisory Network.
The Advisory Network will bring together small molecule drug
discovery and development experts from across the globe. It has
been formed to harness industry expertise to build on C4XD's drug
discovery capabilities and attract valuable relationships that have
the potential to advance its goal of becoming the world's most
productive drug discovery company. Robin and his team will act as
ambassadors for C4XD within the Biotech and Pharmaceutical
community, building awareness of C4XD's technologies, capabilities
and business. Through their extensive relationships and industry
knowledge, they will identify pioneering complementary drug
discovery technologies and collaborators that have the potential to
accelerate or improve delivery of C4XD's portfolio.
Clive Dix, Chief Executive Officer of C4XD, said: "We are
delighted to announce the formation of our Advisory Network and to
be working closely with prestigious world leading experts in drug
discovery. As part of our strategy to become the world's most
productive drug discovery company, we are continually enhancing
both our network and expertise. As international thought leaders,
the Advisory Network's deep industry expertise will enable us to
accelerate progress of our portfolio and we are particularly proud
that Robin will be Chair. Under Robin's guidance, we believe the
Advisory Network will advance our vision and reputation within the
industry."
Robin Carr, added: "C4XD is an inspiring young company at the
forefront of drug discovery with cutting edge technologies and
scientists of the highest calibre. Their openness to collaboration
and working with complementary technologies creates a new frontier
in bringing novel approaches to the creation of future medicines. I
am honoured and excited to be working with the C4XD team and to
building the Advisory Network that will add value in an innovative
and collaborative way."
Chair of the C4XD Drug Discovery Advisory Network - Robin
Carr
Robin has thirty years of experience in drug discovery and has
held senior roles in Glaxo Wellcome, GSK and Astex Therapeutics. At
GSK, he was senior Vice President of Drug Design and Selection and
held global responsibility for GSK's small molecule and biopharm
drug discovery platforms. At Astex Therapeutics, Robin was VP Drug
Discovery, with responsibility for its internal and partnered
discovery programmes.
Robin's scientific focus is innovative approaches to small
molecule drug discovery, specifically fragment-based discovery, DNA
encoded libraries, covalent drug discovery, protein degradation and
the integration of chemical technologies in into structure and
predictive modelling-based drug design.
During his career, Robin has worked on seven small molecule
programmes that have progressed into the clinic, of which, two have
achieved approval within oncology. Robin has published over 40 peer
reviewed papers and patents.
Robin has a PhD in Chemistry from Northwestern University and a
BSc in Organic Chemistry from Imperial College, London.
Further Advisory Network members will be announced in due
course.
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
James Stearns (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
drug discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies
across the drug discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant
value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBFLLBKKFBBBZ
(END) Dow Jones Newswires
September 02, 2019 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Sep 2024 to Oct 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Oct 2023 to Oct 2024